Biology Reference
In-Depth Information
124. Yatsiv I, Grigoriadis N, Simeonidou C, Stahel PF, Schmidt OI, Alexandrovitch AG,
et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neu-
ronal apoptosis and inflammation in a rodent model of experimental closed head injury.
FASEB J 2005;19(12):1701-3.
125. Banks WA, Jumbe NL, Farrell CL, Niehoff ML, Heatherington AC. Passage of erythro-
poietic agents across the blood-brain barrier: a comparison of human and murine eryth-
ropoietin and the analog darbepoetin alfa. Eur J Pharmacol 2004;505(1-3):93-101.
126. Xenocostas A. The pharmacokinetics of erythropoietin in the cerebrospinal fluid after
intravenous administration of recombinant human erythropoietin. Eur J Clin Pharmacol
2005;61(3):189-95.
127. Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV. Erythropoietin
in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clini-
cal trial. Acta Neurochir (Wien) 2007;149(11):1089-101.
128. Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, et al.
Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002;8(8):
495-505.
129. Grasso G, Sfacteria A, Meli F, Fodale V, Buemi M, Lacopino DG. Neuroprotection
by erythropoietin administration after experimental traumatic brain injury. Brain Res
2007;1182:99-105.
130. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, et al.
Erythropoietin crosses the blood-brain barrier to protect against experimental brain
injury. Proc Natl Acad Sci USA 2000;97(19):10526-31.
131. Verdonck O, Lahrech H, Francony G, Carle O, Farion R, Van de Looij Y, et al.
Erythropoietin protects from post-traumatic edema in the rat brain. J Cereb Blood Flow
Metab 2007;27(7):1369-76.
132. Ransome MI, Turnley AM. Systemically delivered erythropoietin transiently enhances
adult hippocampal neurogenesis. J Neurochem 2007;102(6):1953-65.
133. Stirling DP, Khodarahmi K, Liu J, McPhail LT, McBride CB, Steeves JD, et al.
Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal die-
back, and improves functional outcome after spinal cord injury. J Neurosci 2004;24(9):
2182-90.
134. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J. Minocycline, a tetracy-
cline derivative, is neuroprotective against excitotoxicity by inhibiting activation and
proliferation of microglia. J Neurosci 2001;21(8):2580-88.
135. Morimoto N, Shimazawa M, Yamashima T, Nagai H, Hara H. Minocycline inhibits oxi-
dative stress and decreases
in vitro
and
in vivo
ischemic neuronal damage. Brain Res
2005;1044(1):8-15.
136. Xu L, Fagan SC, Waller JL, Edwards D, Borlongan CV, Zheng J, et al. Low dose intrave-
nous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in
rats. BMC Neurol 2004;4(7).
137. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline
derivative, minocycline, reduces inflammation and protects against focal cerebral isch-
emia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96(23):13496-500.
138. Browne KD, Iwata A, Putt ME, Smith DH. Chronic ibuprofen administration worsens cog-
nitive outcome following traumatic brain injury in rats. Exp Neurol 2006;201(2):301-7.
139. McClain C, Coden D, Phillips R, Ott L, Young B. Increased plasma and ventricular fluid
interleukin-6 levels in patients with head injury. J Lab Clin Med 1991;118:225-31.
140. Bell MJ, Kochanek PM, Doughty LA, Carcillo JA, Adelson PD, Clark RS, et al.
Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury
in children. J Neurotrauma 1997;14:451-57.
